A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti
A phase 1/2 trial of Mosunetuzumab, Tocilizumab, Lenalidomide in follicular lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma is a phase 1/2 interventional study registered as NCT04246086 by Hoffmann-La Roche, with 237 participants planned, started 2020-08-12 and due to reach its primary completion in 2030-09-06. Interventions recorded: Mosunetuzumab (IV), Tocilizumab, Lenalidomide, Mosunetuzumab (SC). Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Mosunetuzumab, Lenalidomide, Follicular lymphoma, Roche / Genentech.
- TrialA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Shares Mosunetuzumab, Tocilizumab, Roche / Genentech.
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Mosunetuzumab, Tocilizumab, Roche / Genentech.
- TrialA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Shares Tocilizumab, Lenalidomide, Roche / Genentech.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Follicular lymphoma.
- TrialA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi
Shares Tocilizumab, Roche / Genentech.
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Tocilizumab, Roche / Genentech.
- TrialMIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Shares Lenalidomide, Follicular lymphoma.